Healthy adults receiving a profylactic vaccine to prevent pneumococcal infection
Conditions
Brief summary
PCV20 specific serum IgG, IgM and IgA concentrations pre-PCV20 and 1 month post-PCV20 vaccination
Detailed description
PCV20 specific serum IgG, IgM and IgA pre-PCV20, 1 month and 11 months post-PCV20 vaccination, IgG, IgM and IgA in serum one month post-PCV20 and one month post PPSV23 vaccination, PCV20 specific IgG and IgA concentrations pre-, 1 month and 11 months post-PCV20 vaccination in mucosal lining fluid
Interventions
Sponsors
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PCV20 specific serum IgG, IgM and IgA concentrations pre-PCV20 and 1 month post-PCV20 vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| PCV20 specific serum IgG, IgM and IgA pre-PCV20, 1 month and 11 months post-PCV20 vaccination, IgG, IgM and IgA in serum one month post-PCV20 and one month post PPSV23 vaccination, PCV20 specific IgG and IgA concentrations pre-, 1 month and 11 months post-PCV20 vaccination in mucosal lining fluid | — |
Countries
Netherlands
Outcome results
None listed